{
    "organizations": [],
    "uuid": "554388819ade3ae8eb2b25168298415b51231a3a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-adamas-announces-final-results-fro/brief-adamas-announces-final-results-from-phase-3-open-label-study-of-gocovri-idUSFWN1RW0DE",
    "ord_in_thread": 0,
    "title": "BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19 (Reuters) - Adamas Pharmaceuticals Inc:\n* ADAMAS ANNOUNCES FINAL RESULTS FROM THE TWO-YEAR PHASE 3 OPEN-LABEL STUDY OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA\n* SAYS PATIENTS RECEIVING GOCOVRI EXPERIENCED LONG-TERM DURABILITY FOR UP TO TWO YEARS\n* SAYS SAFETY PROFILE WAS CONSISTENT WITH PREVIOUSLY-PUBLISHED CONTROLLED PHASE 3 STUDIES\n* SAYS RESULTS DEMONSTRATED THAT GOCOVRI WAS GENERALLY WELL TOLERATED Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-19T17:33:00.000+03:00",
    "crawled": "2018-04-20T11:47:26.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "adamas",
        "pharmaceutical",
        "inc",
        "adamas",
        "announces",
        "final",
        "result",
        "phase",
        "study",
        "parkinson",
        "disease",
        "patient",
        "dyskinesia",
        "say",
        "patient",
        "receiving",
        "gocovri",
        "experienced",
        "durability",
        "two",
        "year",
        "say",
        "safety",
        "profile",
        "consistent",
        "controlled",
        "phase",
        "study",
        "say",
        "result",
        "demonstrated",
        "gocovri",
        "generally",
        "well",
        "tolerated",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}